trending Market Intelligence /marketintelligence/en/news-insights/trending/z1r9xlzv-utkccbyltlrcw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Fennec drug secures another US FDA designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Fennec drug secures another US FDA designation

Fennec Pharmaceuticals Inc. secured the U.S. Food and Drug Administration's breakthrough therapy status for its drug Pedmark.

Pedmark prevents ototoxicity, or ear damage, as a side-effect of cisplatin chemotherapy in children with standard-risk hepatoblastoma. Hepatoblastoma is a very rare cancerous tumor that starts in the liver and primarily affects children.

The therapy previously received the FDA's fast track designation. The designation allows the regulator to accelerate the review process for drugs indicated to treat serious and life-threatening conditions.

The breakthrough therapy designation will include all features of the fast track, as well as more intensive FDA guidance on an efficient drug development program.

Research Triangle Park, N.C.-based Fennec is a biopharmaceutical company that develops product candidates for use in the treatment of cancer in the U.S.